{"title":"Dr. Jonas Salk","authors":"Kimberly M. Kleiss MD","doi":"10.1016/S1068-607X(03)00007-6","DOIUrl":null,"url":null,"abstract":"<div><p>Jonas Salk began his career in microbiology working with the inactivated influenza vaccine. He would later use the formalin<span><span> inactivation process to create the poliomyelitis vaccine<span>. Using a newly created modern cell culture technique, Salk was able to mass produce vaccines for the large-scale polio vaccine field trial. Under the direction of Thomas Francis, Jr., the field trial utilized both a double-blinded placebo-controlled trial and an observational study, and included almost 2 million American schoolchildren as subjects. The vaccine proved to be both safe and effective. Although later replaced by the Sabin oral vaccine, the Salk </span></span>inactivated vaccine<span> played a large part in the eventual eradication of polio from the Western Hemisphere. After his work on the polio vaccine, he created the Salk Institute, a private institution dedicated to research. Subsequently, until his death in 1995, Salk conducted research on an HIV vaccine.</span></span></p></div>","PeriodicalId":80301,"journal":{"name":"Primary care update for Ob/Gyns","volume":"10 3","pages":"Pages 127-128"},"PeriodicalIF":0.0000,"publicationDate":"2003-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1068-607X(03)00007-6","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Primary care update for Ob/Gyns","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1068607X03000076","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Jonas Salk began his career in microbiology working with the inactivated influenza vaccine. He would later use the formalin inactivation process to create the poliomyelitis vaccine. Using a newly created modern cell culture technique, Salk was able to mass produce vaccines for the large-scale polio vaccine field trial. Under the direction of Thomas Francis, Jr., the field trial utilized both a double-blinded placebo-controlled trial and an observational study, and included almost 2 million American schoolchildren as subjects. The vaccine proved to be both safe and effective. Although later replaced by the Sabin oral vaccine, the Salk inactivated vaccine played a large part in the eventual eradication of polio from the Western Hemisphere. After his work on the polio vaccine, he created the Salk Institute, a private institution dedicated to research. Subsequently, until his death in 1995, Salk conducted research on an HIV vaccine.